ClinicalTrials.gg
Active, not recruitingNCT07198386Updated Oct 29, 2026

Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of CS060380 and Placebo in NASH, sponsored by Cascade Pharmaceuticals, Inc. Active, not recruiting at 8 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Cascade Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if CS060380 tablets works to treat non-alcoholic steatohepatitis(NASH) in adults.It will also learn about the safety of CS060380 tablets.The main questions it aims to answer are:

  • After 12 weeks of administration, what was the percentage change in fat content evaluated by MRI-PDFF compared to the baseline?
  • What medical problems do participants have when taking CS060380 tablets? Researchers will compare CS060380 tablets to a placebo (a look-alike substance that contains no drug) to see if CS060380 tablets works to treat NASH.

Participants will:

  • Take CS060380 tablets or a placebo every day for 12 weeks
  • Visit the clinic for checkups and tests at the frequency required by the protocol
  • Keep a diary of their symptoms and the number of tablets taken
Read the detailed description

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase IIa clinical trial to evaluate CS060380 tablets in patients with non-alcoholic steatohepatitis (NASH).

This study consists of two parts, Part A and Part B. The plan is to conduct the Part A study first.

Subjects who meet the inclusion criteria will be randomly assigned in a 1:1:1 ratio to group A at 0.25mg, study group B at 0.5mg, and placebo group, with a planned inclusion of 20 subjects in each group.

The sponsor will base on the safety and tolerability results obtained in Part A to decide whether to proceed to Part B.Subjects of Part B who meet the inclusion criteria will be randomly assigned in a 1:1:1 ratio to group C at 1mg, study group D at 2mg, and placebo group, with a planned inclusion of 20 subjects in each group.

Part A and Part B will take the investigational product on an empty stomach once a day at a fixed time as much as possible for 12 consecutive weeks.

02

Conditions studied

  • NASH
03

In context

Lead sponsor

Cascade Pharmaceuticals, Inc is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged 18 to 70 (including the boundary value).
  2. Liver results within 6 months prior to randomization were consistent with the pathological diagnosis of NASH, and the non-alcoholic fatty liver disease activity score (NAS) was ≥4 points, with at least 1 point each for inflammation and balloon changes, and the fibrosis stage of the Clinical Study Network for Non-alcoholic Steatohepatitis (NASH-CRN) in the United States was F1-F3; Or, the liver fat content is confirmed to be ≥ 10% based on the magnetic MRI-PDFF results of this hospital within the previous 3 months..
  3. Participants with fertility and their spouses or partners voluntarily took effective measures from screening to within 3 months after the last administration. Among them, women of childbearing age include premenopausal women and women within two years after menopause, except those who have undergone hysterectomy or bilateral oophorectomy or have medically confirmed ovarian failure.
  4. Before randomization, there were stable and AST results. If the ALT or AST value during the screening period was ≥ 1.5 × (), it is necessary to have continuous 2 stable evidences before randomization (the two evaluations need to be spaced at least 2 weeks apart), and one of the following evidences must be met:

    • Compared with the historical data within 2 weeks to 3 months before the screening process (if any, and the value ≤5×ULN), the ALT or AST value during the screening period needs to increase by ≤30% compared with the historical data.
    • If there is no available historical data and the ALT or AST value during the screening period is greater than 1.5×ULN, the test should be repeated at least once every two weeks. The ALT or AST value after re-testing should increase by no more than 30% compared to the screening period.
  5. Avoid strenuous exercise at least 24 hours before each visit or blood draw.
  6. Sign the ICF before the experiment and be able to complete the research as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. The following liver diseases or past medical history were present at the time of screening:

    1. Patients with other acute or chronic liver diseases or biliary tract diseases not caused by NASH, and the researchers determined that not suitable to participate in this study, Including but not limited to virus, Untreated virus, DILI, ALD, WD, AIH, PBC, PSC.
    2. Has a history of liver cirrhosis.
    3. Primary liver cancer. AFP > 50 μg/L.
  2. During screening, the following medical history was present:

    1. Study the history of allergies to drug ingredients and .
    2. Surgical procedures that may interfere with treatment, including but not limited to weight loss surgery, liver transplantation surgery, etc.
    3. Screen those who have a history of malignant tumors within the previous five years.
    4. for any MRI scan.
    5. Screen for a history of drug or substance abuse within the previous two years.
    6. Screen for a history of heavy drinking for more than three consecutive months within one year prior to the screening.
    7. Weight change ≥ 5% in the first 3 months of randomization or ≥ 10% in the first 6 months of randomization.
    8. Individuals who have donated blood within the past 3 months prior to screening, and those who have lost a total of 400 mL or more due to blood donation or other reasons within the past 6 months.
    9. Merge with any of the following serious cardiovascular disease or surgical histories (including but not limited to):

      1. Unstable angina pectoris occurred within 3 months prior to randomization.
      2. Combined heart failure, ≥ Ⅲ
      3. Myocardial infarction, shock or life-threatening arrhythmia occurred within 6 months prior to randomization.
      4. Randomized coronary artery bypass grafting surgery or percutaneous coronary intervention within the first 6 months.
  3. The following concomitant diseases or conditions occur during the screening period:

    1. T1DM, uncontrolled T2DM ( > 9 % ), history of severe hypoglycemia.
    2. Intestinal diseases that affect the absorption of oral medications.
    3. There are thyroid diseases, including hyperthyroidism and hypothyroidism or pituitary disorders.
    4. Combined with serious diseases such as circulatory, respiratory, urinary, hematological, immune, psychiatric, neurological, and renal disorders, it has been determined by the researchers that it is not suitable to participate in this study.
    5. Uncontrolled hypertension was present during screening: systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg even under regular medication control.
    6. When screening >450 ms (for males) or >470 ms (Female).
    7. When screening, antibody positive and syphilis spiral antibody positive.
    8. Pregnant and lactating women.
    9. Laboratory test:

      1. \<LLN.
      2. > 1.2×, Gilbert Syndrome.
      3. or AST > 5 × ULN.
      4. \< 50 mL/min/1.73 m².
      5. IRN > 1.5.
      6. THS or FT4 abnormality.
      7. Cardiac Troponin > ULN.
  4. The following medication history existed before randomization:

    1. No stable dose of sodium-glucose cotransporter-2 was received within 6 months prior to randomization(SGLT2), PCSK9 inhibitors (unless SGLT2 and PCSK9 inhibitor drugs have been used at a stable dose for at least 6 months).
    2. Use of an excessively high dose of vitamin E within 6 months prior to randomization (unless the dose is stable and \<400 IU/d), pioglitazone, glucagon-like peptide-1 (GLP-1) receptor agonists GIPR/GLP-1R dual agonists, GIPR/GLP-1R/GCGR triple agonists, compound Oral antidiabetic (OAD) regimens (three or more OADs).
    3. Those who have received treatment for NAFLD/NASH including but not limited to the following within 3 months prior to randomization Drugs, FXR agonists, FGF21 analogues, DGAT2 inhibitors, PDE inhibitors Agents, other THR-β agonists, obeticholic acid, etc.
    4. During the first 3 months prior to the randomization, the patients did not use the hypoglycemic drugs at a stable dose (such as metformin, sulfonylurea drugs, dipeptidyl peptidase 4 inhibitors, α-glucosidase inhibitors, thiazolidinediones (except pioglitazone), etc.) (unless these hypoglycemic drugs had been used at a stable dose for at least 3 months).
    5. The fluctuation range of insulin dosage within the previous 3 months was ≥ 30%.
    6. For the first 3 months prior to the randomization, no stable dose of lipid-lowering drugs (such as statins, fibrates, cholesterol absorption inhibitors (such as ezetimibe), niacin, omega-3 fatty acids, etc.) was used (unless these lipid-lowering drugs had been used at a stable dose for at least 3 months).
    7. Within 3 months prior to randomization (for unmarketed drugs or devices) or within 5 half-lives (for marketed drugs), the patient has participated in other product or device clinical trials (if there is evidence that the patient participated in a clinical trial, received treatment in the inactive drug group, or has been removed from the group without receiving treatment with the investigational product, they are eligible to participate in this study for screening).
    8. Having received drug treatment that includes but is not limited to the following drugs that may cause NAFLD/NASH for at least 2 weeks within one month prior to boarding the machine For example, total parenteral nutrition (TPN), amiodarone, methotrexate, systemic , tetracycline, tamoxifen, estrogen with doses greater than those used for or hormone replacement, anabolic steroids, valproic acid and other known liver-toxic drugs.
    9. During the randomization period of the previous 4 weeks or during the clinical study period, the use of hepatoprotective drugs not permitted by the protocol, including but not limited to, silymarin (Bixin), bicyclol, glycyrrhizin preparations (isoglycyrrhizinate, compound glycyrrhizin, glycyrrhizine dihydrogen monophosphate, etc.) and others (except for hepatoprotective drugs such as ursodeoxycholic acid, polyene phosphatidylcholine, reduced glutathione, etc. that have been used stably for at least 3 months with low risk).
    10. Received anticoagulant treatment within 2 weeks prior to randomization: drugs that increase (e.g., FXa inhibitors, warfarin, heparin, etc.).
    11. Those who have used enzyme strong suppressors, CYP3A enzyme strong inducers, inhibitors of P-gp or BCRP transporters that may affect the metabolism or absorption of this drug within 14 days prior to randomization or at least 5 half-lives (whichever is longer).
  5. Other circumstances that the researcher deems unsuitable for inclusion in the trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Part A: Group A of 0.25 mg CS060380

    Take five tablets of 0.05mg CS060380 daily for 12 weeks.

    Drug: CS060380

  • Experimental
    Part A: Group B of 0.5 mg CS060380

    Take one tablet of 0.5mg CS060380 and four tablets of placebo daily for 12 weeks.

    Drug: CS060380 · Drug: Placebo

  • Placebo comparator
    Part A: Placebo

    Take five tablets of placebo daily for 12 weeks.

    Drug: Placebo

  • Experimental
    Part B: Group C of 1 mg CS060380

    Take two tablets of 0.5mg CS060380 and two tablets of placebo daily for 12 weeks.

    Drug: CS060380 · Drug: Placebo

  • Experimental
    Part B: Group D of 2 mg CS060380

    Take four tablets of 0.5mg CS060380 daily for 12 weeks.

    Drug: CS060380

  • Placebo comparator
    Part B: Placebo

    Take four tablets of placebo daily for 12 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. MRI-PDFF

    To assess the changes in liver steatosis through magnetic resonance imaging (MRI) proton density fat fraction (PDFF) from baseline to Week 12.

    Time frame: D85

Secondary outcomes

  1. AE, SAE, Vital signs, Physical examination, 12-ECG, Thyroid function, laboratory tests.

    Safety and Tolerability.

    Time frame: Up to 12 weeks

  2. ALT, AST, GGT, TC, LDL-C, HDL-C, TG, ApoB, Lp(a), The ApoB/ApoA ratio.

    The percentage change in liver injury and lipid metabolic indicators compared to the baseline period.

    Time frame: Up to 12 weeks

  3. Hypersensitive C-reactive protein

    The change of hypersensitive C-reactive protein from baseline.

    Time frame: Up to 12 weeks

  4. MRI-PDFF relative baseline decrease percentage

    Percentage of participants with a relative decrease in fat content (%) assessed by MRI-PDFF of ≥30% compared to baseline.

    Time frame: Baseline to Day 85

  5. ALT relative to baseline decrease ratio

    The proportion of participants whose ALT decreased by more than 17 U/L compared to the baseline.

    Time frame: Up to 12 weeks

  6. Fasting blood glucose, fasting insulin level, HOMA-IR, HbA1c, body weight, and BMI.

    Changes in glucose metabolism related indicators compared to baseline.

    Time frame: Up to 12 weeks

  7. Cmax

    Single-Dose Pharmacokinetic (PK) Parameter: Maximum observed plasma concentration.

    Time frame: Up to 12 weeks

  8. Tmax

    Single-Dose Pharmacokinetic (PK) Parameter: time to the maximum observed plasma concentration.

    Time frame: Up to 12 weeks

  9. T1/2

    Single-Dose Pharmacokinetic (PK) Parameter: elimination half-life.

    Time frame: Up to 12 weeks

  10. CL/F

    Single-Dose Pharmacokinetic (PK) Parameter: apparent total plasma clearance.

    Time frame: Up to 12 weeks

  11. Vd/F

    Single-Dose Pharmacokinetic (PK) Parameter: apparent volume of distribution.

    Time frame: Up to 12 weeks

  12. AUC0-∞

    Single-Dose Pharmacokinetic (PK) Parameter: AUC from time zero to infinity.

    Time frame: Up to 12 weeks

  13. AUC0-24h

    Single-Dose Pharmacokinetic (PK) Parameter: AUC from time zero to 24 hours.

    Time frame: Up to 12 weeks

  14. Cmax,ss

    Multiple-Dose Pharmacokinetic (PK) Parameter: Steady-state peak concentration.

    Time frame: Up to 12 weeks

  15. Tmax,ss

    Multiple-Dose Pharmacokinetic (PK) Parameter: steady-state time to peak.

    Time frame: Up to 12 weeks

  16. Cmin,ss

    Multiple-Dose Pharmacokinetic (PK) Parameter: steady-state trough concentration.

    Time frame: Up to 12 weeks

  17. Cavg,ss

    Multiple-Dose Pharmacokinetic (PK) Parameter: mean steady-state blood drug concentration.

    Time frame: Up to 12 weeks

  18. T1/2,ss

    Multiple-Dose Pharmacokinetic (PK) Parameter: elimination half-life.

    Time frame: Up to 12 weeks

  19. AUCtau

    Multiple-Dose Pharmacokinetic (PK) Parameter: AUC over one dosing interval.

    Time frame: Up to 12 weeks

  20. Rac

    Multiple-Dose Pharmacokinetic (PK) Parameter: accumulation factor.

    Time frame: Up to 12 weeks

  21. The percentage change of sex hormone-binding globulin (SHBG) from baseline.

    Pharmacodynamics

    Time frame: Up to 12 weeks

  22. Change in the Health Survey Short Form (SF-36) relative to baseline.

    Patient-reported outcome

    Time frame: Baseline to day 85

Other outcomes

  1. Use iLivTouch to evaluate the changes of Liver stiffness measurement value (LSM), LIID and Ultrasonic attenuation parameter (UAP) compared to the baseline.

    The influence of CS060380 tablets on improving fibrosis.

    Time frame: Day 1, day 85.

07

Study locations

8 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Jul 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2025
First posted
Sep 30, 2025
StartActual
Sep 30, 2025
Primary completionActual
Jul 21, 2026
CompletionEst.
Nov 30, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 29, 2026
Primary completion
Jul 24, 2026→Jul 21, 2026 (actual)
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    Primary completion Jul 24, 2026→Jul 21, 2026 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07198386
Lead sponsor
Cascade Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Sep 30, 2025
Primary completion
Jul 21, 2026
Completion
Nov 30, 2026 (estimated)
Last update
Oct 29, 2026

Study contacts

Junping Shi, MD
principal investigator · The Affiliated Hospital of Hangzhou Normal University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CS060380

Start the discussion